Novartis

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novartis and other ETFs, options, and stocks.

About NVS

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. 

CEO
Vasant Narasimhan
CEOVasant Narasimhan
Employees
75,883
Employees75,883
Headquarters
Basel, Basel-Stadt (Basle Town)
HeadquartersBasel, Basel-Stadt (Basle Town)
Founded
1996
Founded1996
Employees
75,883
Employees75,883

NVS Key Statistics

Market cap
280.67B
Market cap280.67B
Price-Earnings ratio
17.63
Price-Earnings ratio17.63
Dividend yield
2.52%
Dividend yield2.52%
Average volume
1.73M
Average volume1.73M
High today
$133.15
High today$133.15
Low today
$130.81
Low today$130.81
Open price
$132.53
Open price$132.53
Volume
2.13M
Volume2.13M
52 Week high
$134.24
52 Week high$134.24
52 Week low
$96.06
52 Week low$96.06

Stock Snapshot

Novartis(NVS) stock is priced at $131.01, giving the company a market capitalization of 280.67B. It carries a P/E multiple of 17.63 and pays a dividend yield of 2.5%.

As of 2025-12-10, Novartis(NVS) stock has fluctuated between $130.81 and $133.15. The current price stands at $131.01, placing the stock +0.2% above today's low and -1.6% off the high.

Novartis(NVS) shares are trading with a volume of 2.13M, against a daily average of 1.73M.

In the last year, Novartis(NVS) shares hit a 52-week high of $134.24 and a 52-week low of $96.06.

In the last year, Novartis(NVS) shares hit a 52-week high of $134.24 and a 52-week low of $96.06.

NVS News

Benzinga 10h
Novartis' Investigational Drug Reports Longer Disease Control In Patients With Rare Blood Disorder

Novartis AG (NYSE:NVS) on Tuesday shared results from the VAYHIT2 Phase 3 trial of ianalumab plus eltrombopag in patients with primary immune thrombocytopenia (...

TipRanks 17h
Novartis announces results from Phase III VAYHIT2 trial

Novartis (NVS) announced positive results from VAYHIT2, a Phase III trial evaluating ianalumab plus eltrombopag in patients with primary immune thrombocytopenia...

Seeking Alpha 23h
Novartis inks $1.7 billion drug target agreement with UK’s Relation Therapeutics

Novartis AG (NVS) to pay UK biotech Relation Therapeutics Ltd. as much as $1.7 billion to help find drug targets to treat allergic diseases. The deal aims to c...

Novartis inks $1.7 billion drug target agreement with UK’s Relation Therapeutics

Analyst ratings

52%

of 29 ratings
Buy
31%
Hold
51.7%
Sell
17.2%

More NVS News

TipRanks 2d
Novartis upgraded to Overweight from Neutral at JPMorgan

JPMorgan upgraded Novartis (NVS) to Overweight from Neutral with a price target of CHF 125, up from CHF 95. The firm adjusted ratings in the European pharma gro...

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.